Diabetes mellitus: channeling care through cellular discovery

Area of Science:

• Endocrinology
• Metabolic Diseases
• Molecular Biology

Background:

• Diabetes mellitus (DM) affects a large global population, imposing significant economic burdens.
• Increasing prevalence of Type 1 and Type 2 DM, including in younger populations.
• DM complications involve multiple organ systems, exacerbated by oxidative stress and apoptosis.

Purpose of the Study:

• To explore innovative treatment strategies for DM through understanding its pathological cellular pathways.
• To investigate the potential of nicotinamide and erythropoietin as novel drug discovery platforms for DM.
• To identify cellular pathways and biomarkers associated with DM onset and progression.

Main Methods:

• Review of existing literature on DM pathophysiology and cellular mechanisms.
• Analysis of the roles of nicotinamide (NAD+ precursor) and erythropoietin in metabolic homeostasis and inflammation.
• Examination of associated pathways including cell cycle regulation, protein kinase B, forkhead transcription factors, and Wnt signaling.

Main Results:

• Nicotinamide and erythropoietin pathways are implicated in regulating cellular metabolism and inflammation relevant to DM.
• These pathways are linked to critical cellular processes such as cell cycle regulation and signaling cascades.
• The identified pathways and agents show potential as biomarkers for DM detection and monitoring.

Conclusions:

• Nicotinamide and erythropoietin represent promising avenues for developing novel therapeutic interventions for diabetes mellitus.
• Understanding the molecular mechanisms governing these pathways can enhance strategies for managing DM.
• These pathways may serve as valuable biomarkers for predicting and tracking the progression of diabetes.